Highlights Celon Pharma S.A.

Equities

CLN

PLCLNPH00015

Delayed Warsaw S.E. Other stock markets 10:03:22 2024-05-16 am EDT			5-day change	1st Jan Change
16.8 ^PLN	-0.12%		+4.22%	+8.67%

Apr. 24	Celon Pharma S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Celon Pharma S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Celon Pharma S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 24	CI
Celon Pharma S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 22	CI
Celon Pharma S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-09-20	CI
Celon Pharma S.A. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-24	CI
Celon Pharma S.A. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-26	CI
Celon Pharma S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-23	CI
Celon Pharma S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-09-28	CI
Celon Pharma S.A. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-25	CI
Celon Pharma S.A. Reports Earnings Results for the Full Year Ended December 31, 2021	22-05-01	CI
Celon Pharma S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-29	CI
Celon Pharma S.A. Reports Earnings Results for the Second Quarter Ended June 30, 2021	21-09-30	CI
Celon Pharma Successfully Completes the First Stage of Clinical Research into its CPL'116 Drug Candidate for Treating Autoimmune Diseases	21-08-10	CI
Celon Pharma Files for Approval of Phase II Trial of CPL’280, a Second Generation GPR40 Agonist, in Type 2 Diabetes	21-06-22	CI
Celon Pharma Announces CPL’280, Second Generation Oral GPR40 Agonist, Meets Primary Endpoint in Phase 1 Trial	21-04-01	CI
Celon Pharma Terminates Cooperation with Lupin Atlantis Holdings	21-03-02	CI
Celon Pharma Announces Successful Completion of Phase 1A Trial of CPL’116, JAK-ROCK Inhibitor	21-02-10	CI
Celon Pharma Announces Positive Falkieri Phase II Results in Treatment-Resistant Bipolar Depression	21-01-08	CI
Celon Pharma S.A. Announces Earnings Results for the Third Quarter Ended September 30, 2020	20-11-30	CI
Celon Pharma S.A. Reports Earnings Results for the Half Year Ended June 30, 2020	20-09-25	CI
Celon Pharma S.A. has completed an IPO in the amount of PLN 244.95 million.	16-09-28	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Celon Pharma S.A.

Equities

CLN

PLCLNPH00015

Highlights

Filters